<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075657</url>
  </required_header>
  <id_info>
    <org_study_id>T/IM-NF/Pharma/01/17</org_study_id>
    <nct_id>NCT03075657</nct_id>
  </id_info>
  <brief_title>Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia</brief_title>
  <official_title>Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study has been planned to evaluate the effect of add-on ramelteon on sleep
      pattern/quality and circadian rhythm disruption in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a mental dysfunction of thought, perception and behaviour which can be
      attributed to complex and dynamically interacting perturbations in multiple neurochemical
      systems. Along with these cardinal features of schizophrenia, sleep disorders and disturbed
      circadian rhythm are commonly encountered among patients. Markedly decreased sleep
      efficiency, delayed sleep onset and frequent awakenings are most common observations.
      Endogenous melatonin is a dependable biomarker of circadian rhythmicity and, it has already
      been found that the nocturnal rise of endogenous melatonin is blunted leading to circadian
      dysrhythmia in schizophrenia.

      The antipsychotics prescribed for the condition though cause improvement in the cardinal
      symptoms of the disease but have no significant effect on melatonin levels. The blunted peak
      of night time melatonin secretion are not restored or even decreased even after several
      months therapy with antipsychotics. In this clinical scenario, add-on therapy with sedative/
      hypnotics along with antipsychotics is mandate for a prescription. Previous studies revealed
      that add-on therapy with benzodiazepines can worsen the already existing derangement in
      circadian rhythm by decreasing secretion of nocturnal melatonin. A long term add on therapy
      with benzodiazepines in patients on antipsychotics has been found to have an increased risk
      of death.

      Addition of melatonin to the pharmacotherapy of schizophrenia elevates mood and daytime
      functioning in addition to improved sleep in schizophrenia patients. Melatonin, apart from
      being a hypnotic and circadian rhythm restoring compound, also possess neuroprotective,
      anti-neuroinflammatory and antioxidant properties. The rate limiting step of melatonin
      biosynthetic pathway is the alkylation of serotonin to N- acetyl serotonin, catalyzed by
      enzyme AANAT (aryl-alkylamine- N-acetyl-transferase). Study of AANAT enzyme and its
      modulation to achieve normal rhythmical secretion of melatonin can also be a potential target
      for resynchronising the circadian rhythm.

      Ramelteon is a melatonin receptor agonist approved for treatment of insomnia by the USFDA. It
      exerts its action by acting on MT1 and MT2 receptors at suprachiasmatic nucleus. The long
      term safety of ramelteon has been evaluated by several workers and found no significant
      adverse effects like abuse liability, rebound insomnia and cognitive impairment. In contrast
      to melatonin, it shows higher-binding affinity for MT1 and MT2 receptors, more lipophilic and
      has a longer half-life(t1/2 of melatonin is 20-50 min whereas that of ramelteon is 1-2.6 hrs
      and that of its active melabolite M-II is 2-5 hrs). In addition, ramelteon has been already
      evaluated as a potential adjunctive treatment for learning and memory deficits in
      schizophrenia.

      The sleep and circadian rhythm disorders in schizophrenia have so far been given very less
      importance by researchers and there are limited studies targeting or modulating the melatonin
      pathway. Therefore, proposed study has been planned to evaluate the effect of add-on
      ramelteon on sleep pattern/quality and circadian rhythm disruption in patients with
      schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum melatonin over 4 weeks from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of sleep over 4 weeks from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary melatonin(6MTs) over 4 weeks from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum AANAT enzyme over 4 weeks from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in severity of symptoms of schizophrenia over 4 weeks from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>PANSS Scoring</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Risperidone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone with Ramelteon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol with Ramelteon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone will be prescribed at dose of 2 mg per day</description>
    <arm_group_label>Risperidone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone and Ramelteon</intervention_name>
    <description>Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day</description>
    <arm_group_label>Risperidone with Ramelteon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol will be prescribed at dose of 2 mg per day</description>
    <arm_group_label>Haloperidol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol and Ramelteon</intervention_name>
    <description>Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 2 mg per day</description>
    <arm_group_label>Haloperidol with Ramelteon group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients of either sex with age range 18-65 years with the clinical
             diagnosis of schizophrenia. (DSM-V)

          -  Treatment na√Øve patients or patients who had not taken any treatment for at least 4
             weeks before inclusion.

          -  Legal guardian of patients consenting to participate in the study by signing the
             informed consent form.

        Exclusion Criteria:

          -  Schizoaffective disorder or schizophrenia with somatoform disorders.

          -  Highly agitated patients who need immediate treatment.

          -  Patients who are already under treatment for the presenting conditions.

          -  Patients with comorbid substance abuse or history of organicity

          -  Patients with known history of dementia, obstructive sleep apnoea syndrome, diabetes
             mellitus.

          -  Pregnant and nursing women.

          -  History of allergy or hypersensitivity to ramelteon.

          -  Legal guardian of patients not willing to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DEBASISH HOTA, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, BHUBANESWAR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RITUPARNA MAITI, MD</last_name>
    <phone>9438884191</phone>
    <email>rituparnamaiti@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ARCHANA M, MBBS</last_name>
    <phone>9650482430</phone>
    <email>archanpmv@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences (AIIMS)</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RITUPARNA MAITI, MD</last_name>
      <phone>9438884191</phone>
      <email>rituparnamaiti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>BISWA R MISHRA, MD</last_name>
      <email>brm1678@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Cohrs S. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics. CNS Drugs. 2008;22(11):939-62. Review.</citation>
    <PMID>18840034</PMID>
  </results_reference>
  <results_reference>
    <citation>Wehr TA, Aeschbach D, Duncan WC Jr. Evidence for a biological dawn and dusk in the human circadian timing system. J Physiol. 2001 Sep 15;535(Pt 3):937-51.</citation>
    <PMID>11559786</PMID>
  </results_reference>
  <results_reference>
    <citation>Afonso P, Figueira ML, Paiva T. Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract. 2011 Nov;15(4):311-5. doi: 10.3109/13651501.2011.605954. Epub 2011 Aug 28.</citation>
    <PMID>22122006</PMID>
  </results_reference>
  <results_reference>
    <citation>Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry. 2012 Apr;200(4):308-16. doi: 10.1192/bjp.bp.111.096321. Epub 2011 Dec 22.</citation>
    <PMID>22194182</PMID>
  </results_reference>
  <results_reference>
    <citation>Mann K, Rossbach W, M√ºller MJ, M√ºller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology. 2006 Feb;31(2):256-64. Epub 2005 Sep 26.</citation>
    <PMID>16185814</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohrs S, Pohlmann K, Guan Z, Jordan W, Meier A, Huether G, R√ºther E, Rodenbeck A. Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl). 2004 Jul;174(3):414-20. Epub 2004 Jan 20.</citation>
    <PMID>14735295</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson S, Rosca P, Durst R, Shai U, Ghinea C, Schmidt U, Nir I. Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients. Acta Psychiatr Scand. 1991 Sep;84(3):221-4.</citation>
    <PMID>1950621</PMID>
  </results_reference>
  <results_reference>
    <citation>Monteleone P, Natale M, La Rocca A, Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology. 1997;36(4):159-63.</citation>
    <PMID>9396013</PMID>
  </results_reference>
  <results_reference>
    <citation>Hajak G, Rodenbeck A, Bandelow B, Friedrichs S, Huether G, R√ºther E. Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Eur Neuropsychopharmacol. 1996 May;6(2):149-53.</citation>
    <PMID>8791041</PMID>
  </results_reference>
  <results_reference>
    <citation>Kabuto M, Namura I, Saitoh Y. Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans. Endocrinol Jpn. 1986 Jun;33(3):405-14.</citation>
    <PMID>3757924</PMID>
  </results_reference>
  <results_reference>
    <citation>Baandrup L, Fagerlund B, Jennum P, Lublin H, Hansen JL, Winkel P, Gluud C, Oranje B, Glenthoj BY. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. BMC Psychiatry. 2011 Oct 5;11:160. doi: 10.1186/1471-244X-11-160.</citation>
    <PMID>21975110</PMID>
  </results_reference>
  <results_reference>
    <citation>Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms. 1997 Dec;12(6):657-65. Review.</citation>
    <PMID>9406042</PMID>
  </results_reference>
  <results_reference>
    <citation>Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Feb;68(2):237-41.</citation>
    <PMID>17335321</PMID>
  </results_reference>
  <results_reference>
    <citation>Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. Review.</citation>
    <PMID>19228178</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57.</citation>
    <PMID>17015817</PMID>
  </results_reference>
  <results_reference>
    <citation>Spadoni G, Bedini A, Lucarini S, Mor M, Rivara S. Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1145-56. doi: 10.1517/17425255.2015.1045487. Epub 2015 May 8. Review.</citation>
    <PMID>25956235</PMID>
  </results_reference>
  <results_reference>
    <citation>Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.</citation>
    <PMID>3616518</PMID>
  </results_reference>
  <results_reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>RITUPARNA MAITI</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

